The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
